Finasteride versus dutasteride: A real-world economic evaluation

American Journal of Managed Care

Volumn 13, Issue 1 SUPPL., 2007, Pages

  Fenter, Thomas C ^a   Runken, M Chris ^b   Black, Libby ^b   Eaddy, Michael ^b  

^a Blue Cross and Blue Shield of Mississippi   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; ARTICLE; COST OF ILLNESS; EMERGENCY WARD; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HOSPITAL CARE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OUTPATIENT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME; URINE RETENTION;

AGED; AZASTEROIDS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FINASTERIDE; HEALTH CARE COSTS; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PROSTATIC HYPERPLASIA; REGISTRIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; WORLD HEALTH;

EID: 33847238807     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate. 1990;17:241-246.
2. Loeb SJ. Older men's health: motivation, self-ratings, and behaviors. Nurs Res. 2004;53:198-206.
3. Tudiver F, Talbot Y. Why don't men seek help? Family physicians' perspectives on help-seeking behavior in men. J Fam Pract. 1999;48:47-52.
4. Fenter TC, Naslund MJ, Shah MB, Eaddy MT, Black L. The cost of treating the 10 most prevalent diseases in men 50 years of age or older. Am J Manag Care. 2006;12(4 suppl):S90-S98.
5. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;18:2387-2398.
6. Proscar® (finasteride) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; 2004.
7. Avodart® (dutasteride) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2005.
8. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Hyattsville, Md: Centers for Disease Control and Prevention; 1979.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
10. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
11. Disease Staging: Coded Criteria. 5th ed. Ann Arbor, Mich: Thomson Medstat; 2003.
12. Etzioni RD, Feuer EJ, Sullivan SD, Lin D, Hu C, Ramsey SD. On the use of survival techniques to estimate medical care costs. J Health Econ. 1999;18:365-380.